10-Q: Moderna Reports Q2 2024 Results: Revenue Declines Amidst Market Shift, RSV Vaccine Approved

Moderna's Q2 2024 results show a decrease in revenue due to the evolving COVID-19 vaccine market, alongside the FDA approval of their RSV vaccine.

Summary

• Moderna's net product sales for Q2 2024 were $184 million, a decrease from $293 million in Q2 2023, primarily due to lower COVID-19 vaccine sales and a shift towards a seasonal market.
• The company reported a net loss of $1.279 billion, or $3.33 per share, for the second quarter of 2024, compared to a net loss of $1.380 billion, or $3.62 per share, in the same period last year.
• Total revenue for Q2 2024 was $241 million, down from $344 million in Q2 2023.
• Cost of sales decreased significantly to $115 million in Q2 2024 from $731 million in Q2 2023, due to lower sales volume and reduced inventory write-downs.
• Research and development expenses increased slightly to $1.221 billion in Q2 2024 from $1.148 billion in Q2 2023.
• Selling, general, and administrative expenses decreased to $268 million in Q2 2024 from $332 million in Q2 2023.
• Moderna's RSV vaccine, mRESVIA, was approved by the FDA in May 2024 for adults aged 60 and older, marking their second approved mRNA product.
• The company has updated its COVID-19 vaccine to target the KP.2 and JN.1 strains and is preparing for the 2024-2025 vaccination season.
• Moderna has a diverse pipeline of 47 development programs, with 43 in clinical studies.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive developments such as the RSV vaccine approval and progress in the pipeline, the significant decline in revenue and net loss are concerning. The company is navigating a challenging transition in the COVID-19 vaccine market, and its future performance will depend on its ability to diversify its revenue streams and manage costs effectively.

Positives

• The FDA approved Moderna's RSV vaccine, mRESVIA, marking the company's second approved mRNA product.
• Moderna's next-generation COVID-19 vaccine candidate (mRNA-1283) demonstrated non-inferior efficacy compared to Spikevax in a Phase 3 trial.
• The combination vaccine candidate against influenza and COVID-19 (mRNA-1083) showed higher immune responses than licensed vaccines in adults 50 years and older.
• The individualized neoantigen therapy (INT) program with Merck showed sustained improvement in recurrence-free survival in melanoma patients.
• Moderna's investigational therapeutic for MMA was selected for the FDA's START pilot program, which will help accelerate its development.
• Cost of sales decreased significantly due to lower sales volume and reduced inventory write-downs.
• The company received up to $176 million from BARDA to accelerate the development of mRNA-based pandemic influenza vaccines.

Negatives

• Net product sales decreased significantly to $184 million in Q2 2024 from $293 million in Q2 2023.
• The company reported a net loss of $1.279 billion in Q2 2024.
• Total revenue decreased by 30% in Q2 2024 compared to Q2 2023.
• The company is experiencing a transition to a seasonal commercial pattern for the COVID-19 vaccine market, leading to reduced demand in the first half of the year.
• The company has a global valuation allowance against the majority of its deferred tax assets, which impacts the effective tax rate.

Risks

• The evolving nature of the COVID-19 vaccine market and its transition to a seasonal pattern may lead to continued fluctuations in revenue.
• The company faces risks related to the development and commercialization of novel medicines, including unforeseen expenses, delays, and other unknown factors.
• Moderna's reliance on third-party suppliers and manufacturers poses risks to its ability to successfully manufacture and distribute its products.
• The company is subject to intellectual property litigation, which could impact its business.
• The company has significant future capital requirements, including operating expenses and capital expenditures, which may lead to continued negative cash flows from operations.
• The company's forecast of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement and involves risks and uncertainties.

Future Outlook

Moderna anticipates that the demand for its COVID-19 vaccine will be higher in the fall and winter seasons. The company expects the full year cost of sales as a percentage of net product sales for 2024 to be lower than the 70% experienced in 2023. Moderna also expects a modest reduction in research and development expenses in 2024 compared to 2023 levels. The company believes that its cash, cash equivalents, and investments, together with cash expected to be generated from product sales, will be sufficient to fund its operations and capital expenditures through at least the next 12 months.

Management Comments

• Moderna is prepared to meet the anticipated 2024-2025 season demand for its updated COVID-19 vaccine.
• The company is committed to investing in its business for future product launches.
• Moderna is focused on advancing its program development and enhancing its overall business processes.

Industry Context

Moderna's results reflect the broader shift in the COVID-19 vaccine market from a pandemic response to a seasonal commercial model. The approval of their RSV vaccine and progress in other pipeline programs position them to diversify their revenue streams beyond COVID-19. The company's focus on mRNA technology and its ability to rapidly adapt to emerging variants are key competitive advantages in the biotechnology industry.

Comparison to Industry Standards

• Moderna's Q2 2024 results show a significant decline in COVID-19 vaccine sales, which is consistent with the broader industry trend of reduced demand as the pandemic transitions to an endemic phase. This is similar to what other vaccine manufacturers like Pfizer and BioNTech have experienced.
• The approval of Moderna's RSV vaccine, mRESVIA, puts them in direct competition with other pharmaceutical companies that have also developed RSV vaccines, such as GSK and Pfizer. The efficacy data of mRESVIA, with a vaccine efficacy against RSV lower respiratory tract disease (LRTD) of 83.7%, is comparable to the efficacy data of other approved RSV vaccines.
• Moderna's research and development expenses remain high, reflecting their commitment to advancing their pipeline. This is in line with other biotechnology companies that are heavily investing in R&D to develop new therapies and vaccines.
• The company's cost of sales as a percentage of net product sales is expected to improve in the second half of 2024, which is a positive sign compared to the high costs experienced in 2023. This is a key metric that investors will be watching closely.
• Moderna's individualized neoantigen therapy (INT) program is a unique approach to cancer treatment, and the positive data from their collaboration with Merck is a significant development. This puts them in a competitive position in the immuno-oncology space, which is a rapidly growing area of the pharmaceutical industry.

Legal Proceedings

• Moderna is involved in various claims and legal proceedings, including intellectual property litigation.
• The company has initiated patent infringement proceedings against Pfizer and BioNTech in the U.S. and Europe.
• In July 2024, the High Court of Justice of England & Wales issued a judgment confirming the validity of the 949 patent and finding that Pfizer and BioNTech had infringed the patent, while determining that the 565 patent was invalid.
• In December 2023, the District Court of The Hague issued a first instance decision determining that the 949 patent was invalid in the Netherlands, which Moderna has appealed.

Stakeholder Impact

• Shareholders are impacted by the decrease in revenue and net loss, but also by the positive developments in the pipeline and the approval of the RSV vaccine.
• Employees are impacted by the company's ongoing research and development efforts and the expansion of its global commercial infrastructure.
• Customers, including governments, healthcare providers, and individuals, will benefit from the availability of new vaccines and therapies.
• Suppliers and contract manufacturing organizations are impacted by the company's purchase commitments and ongoing manufacturing activities.
• Creditors are impacted by the company's financial performance and its ability to meet its obligations.

Next Steps

• Moderna will continue to advance its pipeline programs, including its next-generation COVID-19 vaccine, combination vaccines, and individualized neoantigen therapy.
• The company will focus on commercializing its RSV vaccine, mRESVIA, and preparing for the 2024-2025 vaccination season with its updated COVID-19 vaccines.
• Moderna will continue to work with regulators worldwide to support registration and supply of its vaccines.
• The company will continue to evaluate the design and operational effectiveness of its internal controls following the implementation of a new ERP system.

Key Dates

Keywords

mRNA, vaccine, COVID-19, RSV, mRESVIA, Spikevax, clinical trials, intellectual property, revenue, net loss, research and development, FDA, BARDA, influenza, neoantigen therapy